Literature DB >> 16115854

Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function.

Craig L Nelson1, Connie S Karschimkus, George Dragicevic, David K Packham, Andrew M Wilson, David O'Neal, Gavin J Becker, James D Best, Alicia J Jenkins.   

Abstract

BACKGROUND: Inflammation is implicated in cardiovascular disease (CVD) and mortality in end-stage renal failure (ESRF). Its importance in early renal disease is yet to be defined.
METHODS: Serum levels of systemic and vascular inflammatory markers in early IgA nephropathy (IgAN) and control subjects were measured and related to renal function and vascular risk factors. A parallel study in type 1 diabetes mellitus subjects with (T1DM Nx) and without nephropathy (T1DM No Nx) was performed.
RESULTS: Fifty-one IgAN patients aged 46+/-2 years (mean+/-SEM), calculated creatinine clearance (CrCl) 88+/-5 ml/min, were compared with 51 matched control subjects. Forty-six T1DM Nx patients aged 40+/-2 years, CrCl 84+/-5 ml/min, and 73 T1DM No Nx patients aged 38+/-2 years were also compared. High sensitivity C-reactive protein (hsCRP) was elevated in IgAN, T1DM Nx and T1DM No Nx patients compared with controls [4.2+/-0.6 (P < 0.001), 4.1+/-0.6 (P < 0.001), 2.6+/-0.4 (P < 0.05) vs 1.6+/-0.3 mg/l]. Levels in T1DM Nx patients were higher than in T1DM No Nx patients (P < 0.05). Inflammation and vascular dysfunction as measured by pulse pressure (PP) were related. HsCRP correlated with PP in IgAN and T1DM Nx (r = 0.47, P = 0.001; r = 0.40, P < 0.05). PP was the strongest independent predictor of hsCRP in IgAN (T = 2.45, P < 0.001), while body mass index (T = 7.83, P < 0.001) was the strongest predictor in T1DM Nx. Endothelial cell adhesion molecules were increased in T1DM Nx > IgAN > T1DM No Nx vs controls: soluble vascular adhesion molecule-1 (sVCAM-1) 760+/-30 (P < 0.001) > 663+/-34 (P = 0.001) > 601+/-21 (P < 0.05) vs 536+/-15 ng/ml; soluble intracellular adhesion molecule-1 (sICAM-1) 320+/-8 (P < 0.001) > 313+/-13 (P < 0.001) > 307+/-8 (P < 0.001) vs 244+/-6 ng/ml. sVCAM-1 levels were higher in T1DM Nx than in T1DM No Nx, P < 0.001. In IgAN and T1DM Nx, hsCRP correlated with sICAM-1 (r = 0.33, P = 0.017; r = 0.37; P = 0.017). sVCAM-1 was related to renal function in IgAN and T1DM Nx: serum cystatin C (r = 0.63, P < 0.001: r = 0.425, P = 0.002), and urine protein:creatinine ratio in IgAN (r = 0.48; P = 0.001).
CONCLUSIONS: Systemic and vascular markers of inflammation are increased in early renal disease and relate to renal dysfunction and cardiovascular risk factors. Inflammation may be a common process in various renal diseases and may link and accelerate renal dysfunction and CVD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115854     DOI: 10.1093/ndt/gfi067

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  26 in total

1.  Heritability of renal function and inflammatory markers in adult male twins.

Authors:  Paolo Raggi; Shaoyong Su; Cristina Karohl; Emir Veledar; Enrique Rojas-Campos; Viola Vaccarino
Journal:  Am J Nephrol       Date:  2010-08-17       Impact factor: 3.754

Review 2.  Role of triglyceride-rich lipoproteins in diabetic nephropathy.

Authors:  John C Rutledge; Kit F Ng; Hnin H Aung; Dennis W Wilson
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

3.  Risk of Cardiovascular Disease and Mortality in Young Adults With End-stage Renal Disease: An Analysis of the US Renal Data System.

Authors:  Zubin J Modi; Yee Lu; Nan Ji; Alissa Kapke; David T Selewski; Xue Dietrich; Kevin Abbott; Brahmajee K Nallamothu; Douglas E Schaubel; Rajiv Saran; Debbie S Gipson
Journal:  JAMA Cardiol       Date:  2019-04-01       Impact factor: 14.676

4.  Role of triglyceride-rich lipoproteins in renal injury.

Authors:  Kit Fai Ng; Hnin Hnin Aung; John C Rutledge
Journal:  Contrib Nephrol       Date:  2011-06-09       Impact factor: 1.580

5.  Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.

Authors:  Alicia J Jenkins; Jeremy Yu; Petar Alaupovic; Arpita Basu; Richard L Klein; Maria Lopes-Virella; Nathaniel L Baker; Kelly J Hunt; Daniel T Lackland; W Timothy Garvey; Timothy J Lyons
Journal:  J Diabetes Complications       Date:  2013-07-11       Impact factor: 2.852

6.  Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.

Authors:  R Kodera; K Shikata; H U Kataoka; T Takatsuka; S Miyamoto; M Sasaki; N Kajitani; S Nishishita; K Sarai; D Hirota; C Sato; D Ogawa; H Makino
Journal:  Diabetologia       Date:  2011-01-21       Impact factor: 10.122

7.  Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes.

Authors:  Monika A Niewczas; Linda H Ficociello; Amanda C Johnson; William Walker; Elizabeth T Rosolowsky; Bijan Roshan; James H Warram; Andrzej S Krolewski
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 8.237

8.  Increased serum kallistatin levels in type 1 diabetes patients with vascular complications.

Authors:  Alicia J Jenkins; Jeffrey D McBride; Andrzej S Januszewski; Connie S Karschimkus; Bin Zhang; David N O'Neal; Craig L Nelson; Jasmine S Chung; C Alex Harper; Timothy J Lyons; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-09-22

9.  Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors.

Authors:  Cecil Stanley Thompson
Journal:  World J Diabetes       Date:  2013-08-15

10.  Relations of measures of endothelial function and kidney disease: the Framingham Heart Study.

Authors:  Meredith C Foster; Michelle J Keyes; Martin G Larson; Joseph A Vita; Gary F Mitchell; James B Meigs; Ramachandran S Vasan; Emelia J Benjamin; Caroline S Fox
Journal:  Am J Kidney Dis       Date:  2008-07-09       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.